Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Balkan Journal of Medical Genetics de Gruyter

Differential expression of FGFRs signaling pathway components in bladder cancer: A step toward personalized medicine

Download PDF
7 pages

Loading next page...
 
/lp/de-gruyter/differential-expression-of-fgfrs-signaling-pathway-components-in-cQMwSQGUsg

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
de Gruyter
Copyright
© 2017 Ousati Ashtiani Z, Tavakkoly-Bazzaz J, Salami SA, Pourmand MR, Mansouri F, Mashahdi R, Pourmand G, published by Sciendo
ISSN
1311-0160
eISSN
1311-0160
DOI
10.1515/bjmg-2017-0026
Publisher site
See Article on Publisher Site

Abstract

Journal

Balkan Journal of Medical Genetics – de Gruyter

Published: Dec 29, 2017

References

  • FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients
  • Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: Implications for therapeutic targeting
  • Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
  • Epigenetics and gene expression
  • Genetic and epigenetic alterations in bladder cancer
  • Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors
  • A correlation between decreased parathyroid alpha-Klotho and fibroblast growth factor receptor 1 expression with pathological category and parathyroid gland volume in dialysis patients
  • Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
  • Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma
  • Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients
  • A correlation between decreased parathyroid alpha-Klotho and fibroblast growth factor receptor 1 expression with pathological category and parathyroid gland volume in dialysis patients
  • Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes
  • Mechanisms of FG-FR-mediated carcinogenesis
  • Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer
  • Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity
  • Fibroblast growth factors and their receptors in cancer
  • Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
  • FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
  • Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer
  • Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
  • FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell
  • Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer
  • Epigenetics and gene expression
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
  • Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
  • FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy
  • Fibroblast growth factors and their receptors in cancer
  • Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
  • FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer
  • FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer
  • FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy
  • FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients
  • FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy
  • Cell signaling and cancer
  • Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors
  • Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer
  • Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: Implications for therapeutic targeting
  • Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer
  • FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell
  • Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes
  • FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
  • Expression of fibroblast growth factor receptor 3 in the recurrence of nonmuscle-invasive urothelial carcinoma of the bladder
  • Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer
  • Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor
  • Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
  • Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity
  • A decade of FGF receptor research in bladder cancer: Past, present, and future challenges
  • Expression of fibroblast growth factor receptor 3 in the recurrence of nonmuscle-invasive urothelial carcinoma of the bladder
  • A decade of FGF receptor research in bladder cancer: Past, present, and future challenges
  • Fibroblast growth factor receptor 1 and cytokeratin 20 expressions and their relation to prognostic variables in bladder cancer
  • The fibroblast growth factor signaling pathway
  • The fibroblast growth factor signaling pathway
  • Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer
  • Complexity of FGFR signalling in metastatic urothelial cancer
  • FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy
  • Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events
  • Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients
  • Complexity of FGFR signalling in metastatic urothelial cancer
  • Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer
  • Genetic and epigenetic alterations in bladder cancer
  • Mechanisms of FG-FR-mediated carcinogenesis
  • Cell signaling and cancer
  • Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events
  • Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma